Moderna, Inc. (MRNA) Tax Rate: -1.95%
Is Moderna, Inc.’s tax rate high or low?
Moderna, Inc.'s tax rate of -1.95% is 5187% below its 5-year average of 0.04%, around the middle of its 5-year range (-19.58%–12.67%).
The tax rate for Moderna, Inc. (MRNA) is -1.95%. It is below its 12-month average by 482.09% (-0.33%).
MRNA Tax Rate Chart
MRNA Average Tax Rate Chart
MRNA Current vs Average Tax Rate Chart
MRNA Tax Rate Metrics
TAX RATE
-1.95%
TAX RATE AVG TTM
-0.33%
TAX RATE AVG 3Y
-1.89%
TAX RATE AVG 5Y
0.04%
TAX RATE AVG 10Y
-0.01%
TAX RATE AVG 15Y
-0.01%
TAX RATE AVG 20Y
-0.01%
CURRENT VS TTM AVG
-482.09%
CURRENT VS 3Y AVG
-2.90%
CURRENT VS 5Y AVG
-5186.96%
CURRENT VS 10Y AVG
-12900.00%
CURRENT VS 15Y AVG
-12900.00%
CURRENT VS 20Y AVG
-12900.00%
Moderna, Inc. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Moderna, Inc. Tax Rate FAQ
- What is the tax rate for Moderna, Inc. (MRNA)?
- The tax rate for MRNA stock is -1.95%.
- Is Moderna, Inc.'s tax rate high or low?
- Moderna, Inc.'s tax rate of -1.95% is 5187% below its 5-year average of 0.04%, around the middle of its 5-year range (-19.58%–12.67%).
- What is the TTM average tax rate for Moderna, Inc. (MRNA)?
- The TTM average tax rate for MRNA stock is -0.33%.
- What is the 3Y average tax rate for Moderna, Inc. (MRNA)?
- The 3Y average tax rate for MRNA stock is -1.89%.
- What is the 5Y average tax rate for Moderna, Inc. (MRNA)?
- The 5Y average tax rate for MRNA stock is 0.04%.
- What is the 10Y average tax rate for Moderna, Inc. (MRNA)?
- The 10Y average tax rate for MRNA stock is -0.01%.
- What is the 15Y average tax rate for Moderna, Inc. (MRNA)?
- The 15Y average tax rate for MRNA stock is -0.01%.
- What is the 20Y average tax rate for Moderna, Inc. (MRNA)?
- The 20Y average tax rate for MRNA stock is -0.01%.
Moderna, Inc. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | -1.95% |
| 2024-12-31 | 1.28% |
| 2023-12-31 | -19.58% |
| 2022-12-31 | 12.67% |
| 2021-12-31 | 8.15% |
| 2020-12-31 | -0.34% |
| 2019-12-31 | 0.14% |
| 2018-12-31 | -0.07% |
| 2017-12-31 | 0.03% |
| 2016-12-31 | -0.48% |
Related Metrics
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel